REG - AstraZeneca PLC - Total Voting Rights
RNS Number : 8642OAstraZeneca PLC01 February 20191 February 2019 15:00 GMT
Transparency Directive
Voting Rights and Capital
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 January 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,267,101,448 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,267,101,448.
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations
Gonzalo Viña
UK/Global
+44 203 7495916
Karen Birmingham
UK/Global
+44 203 7495634
Rob Skelding
UK/Global
+44 203 7495821
Matt Kent
UK/Global
+44 203 7495906
Jennifer Hursit
UK/Global
+44 203 7495762
Christina M Hägerstrand
Sweden
+46 8 552 53 106
Michele Meixell
US
+1 302 885 2677
Investor Relations
Thomas Kudsk Larsen
+44 203 7495712
Henry Wheeler
Oncology
+44 203 7495797
Christer Gruvris
BioPharma - Cardiovascular; Metabolism
+44 203 7495711
Nick Stone
BioPharma - Respiratory; Renal
+44 203 7495716
Josie Afolabi
Other
+44 203 7495631
Craig Marks
Finance; Fixed Income
+44 7881 615764
Jennifer Kretzmann
Retail Investors; Corporate Access
+44 203 7495824
US toll-free
+1 866 381 72 77
Adrian Kemp
Company SecretaryAstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDTVRLLFLFFSILIIA
Recent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Agreement with US Govt to lower medicine prices
AnnouncementRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
Announcement